Ownership and insider activity for Jasper Therapeutics, Inc. (JSPR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
Price
| Price | $0.58 |
| Market Cap | $9M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-31 | WIGGANS THOMAS G | A-Award | 7,500 | $5K |
| 2026-07-31 | Lucas Svetlana | A-Award | 7,500 | $5K |
| 2026-07-31 | Crutcher Patrick J | A-Award | 7,500 | $5K |
| 2026-07-31 | EMSTER KURT VON | A-Award | 7,500 | $5K |
| 2026-07-31 | Shizuru Judith Anne | A-Award | 7,500 | $5K |
| 2026-07-16 | Keenan Greg | 103,204 | $1K | |
| 2026-07-16 | Keenan Greg | 92,278 | $56K | |
| 2026-07-20 | Ros Matthew E | P-Purchase | 881 | |
| 2026-07-16 | Song Wenru | |||
| 2026-07-16 | Song Wenru |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.2M | $19.8M | $84.7M | $38.2M | $86.9M | $71.6M | $28.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $600000 | 0 | 0 | $250000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $27.2M | $20.7M | $87.8M | $41.7M | $88.9M | $75.8M | $34.6M |
| Property, Plant & Equipment | 0 | $2.0M | $4.8M | $5.5M | $4.2M | $2.9M | $604000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $27.2M | $23.4M | $93.7M | $48.4M | $94.9M | $79.9M | $35.8M |
| Accounts Payable | $623000 | $1.4M | $3.9M | $1.8M | $4.1M | $4.0M | $6.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.0M | $4.0M | $8.0M | $7.1M | $12.4M | $15.2M | $13.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.1M | $58.5M | $24.1M | $12.4M | $16.5M | $18.2M | $31.6M |
| Retained Earnings | -$5.1M | -$36.8M | -$67.5M | -$105.1M | -$169.6M | -$240.9M | -$316.7M |
| Total Equity | $21.1M | -$35.1M | $69.5M | $36.0M | $78.4M | $61.7M | $4.2M |
| Total Debt | 0 | $1.6M | $2.9M | $3.7M | $2.8M | $1.8M | $1.2M |
| Net Debt | -$27.2M | -$18.2M | -$81.8M | -$34.6M | -$84.1M | -$69.8M | -$27.5M |
| Working Capital | $25.2M | $16.7M | $79.8M | $34.7M | $76.6M | $60.6M | $21.4M |
Financial Health
| Debt / Equity | 0.19 |
| Current Ratio | 1.47 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -18.43 |
Profitability
| Return on Equity | -618.87% |
| Return on Invested Capital | -1305.04% |
| Return on Assets | -269.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLD · BTAI · CELU · GBIO · MURA · NXTC · PSTV
Explore sector: Healthcare · Biotechnology
More sections of JSPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks